Abstract
This randomized trial evaluated the effect of zoledronic acid on femoral bone mineral
density (BMD) following primary total hip arthroplasty. Bone mineral density was compared
for up to 2 years in 27 patients receiving 5 mg zoledronic acid intravenous infusion and in 24 patients receiving placebo at 2 weeks and 1 year after surgery. Zoledronic acid prevented loss of bone mineral density at 1 year (+13.8% vs +1.4%, P=.0065) and 2 years (+14.3% vs −4.0%, P<.0001) in Gruen zone 1, at 1 year (−8.4% vs −25.4%, P<.0001) and 2 years (−9.6% vs −27.3%, P<.0001) in Gruen zone 7, at 6 weeks, 6 months, and 1 or 2 years in Gruen zones 4 and 6. For all Gruen zones, prevention of BMD loss by ZOL was
significant at 6 weeks, 6 months, 1 year (+0.80% vs −6.03%, P<.0001) and 2 years (-0.16% vs −7.13%, P<.0001).
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of ArthroplastyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Determination of bone mineral density by dual x-ray absorptiometry in patients with uncemented total hip arthroplasty.J Orthop Res. 1992; 10: 836
- Measurement of bone mineral density by dual-energy x-ray absorptiometry in patients with the Wisconsin hip, an uncemented femoral stem.J Arthroplasty. 1996; 11: 184
- Host-bone response to porous-coated cobalt-chrome and hydroxyapatite-coated titanium femoral components in hip arthroplasty. Dual-energy x-ray absorptiometry analysis of paired bilateral cases at 5 to 7 years.J Arthroplasty. 1996; 11: 429
- Pathogenesis of bone loss after total hip arthroplasty.Orthop Clin North Am. 1998; 29: 173
- The relationship between stress shielding and bone resorption around total hip stems and the effects of flexible materials.Clin Orthop Relat Res. 1992; 274: 124
Questions and answers about hip replacement. Bethesda, MD: National Institute of Arthritis and Musculoskeletal and Skin Diseases. Available at: http://www.niams.nih.gov/Health_Info/Hip_Replacement/default.asp. Accessed December 2, 2010.
- Joint replacement access in 2006. A supply side crisis.J Arthroplasty. 2010; : 1175
- Effects of alendronate in total hip arthroplasty.J Bone Joint Surg Br. 1999; 81: 313
- Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study.J Bone Miner Res. 2001; 16: 2126
- Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial.J Bone Miner Res. 2001; 16: 556
- Dose-dependent prevention of early periprosthetic bone loss by alendronate.Z Orthop Ihre Grenzgeb. 2002; 140: 42
- Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis.J Bone Joint Surg Am. 2005; 87: 293
- Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial.J Orthop Res. 2005; 23: 1
- Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplasty.J Orthop Sci. 2005; 10: 32
- Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study.J Orthop Res. 2006; 24: 1336
- Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomised study.Acta Orthop Belg. 2006; 72: 44
- Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty.Osteoporos Int. 2007; 18: 1009
- Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty.J Orthop Res. 2009; 27: 183
- Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.N Engl J Med. 2007; 356: 1809
- Zoledronic acid and clinical fractures and mortality after hip fracture.N Engl J Med. 2007; 357: 1799
- Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.Obstet Gynecol. 2009; 114: 999
- The decrease of particle-induced osteolysis after a single dose of bisphosphonate.Biomaterials. 2005; 26: 1803
- Stimulation of bone formation by zoledronic acid in particle-induced osteolysis.Biomaterials. 2005; 26: 3719
- Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog.Calcif Tissue Int. 2005; 77: 367
- Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration.Bone. 2005; 36: 52
- The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial.J Bone Joint Surg Am. 2009; 91: 274
- Longitudinal evaluation of time related bone remodeling after cementless total hip arthroplasty.Clin Orthop Relat Res. 1997; 339: 121
- Periprosthetic bone remodelling of two types of uncemented femoral implant with proximal hydroxyapatite coating: a 3-year follow-up study addressing the influence of prosthesis design and preoperative bone density on periprosthetic bone loss.Osteoporos Int. 2004; 15: 281
- Clinical and radiological outcome of total hip replacement five years after pamidronate therapy. A trial extension.J Bone Joint Surg Br. 2006; 88: 1309
- Epidemiology and pathogenesis of osteonecrosis of the jaw.Nat Rev Rheumatol. 2011; 29: 90
- Systematic review: bisphosphonates and osteonecrosis of the jaws.Ann Intern Med. 2006; 144: 753
Article info
Publication history
Published online: November 12, 2012
Accepted:
August 5,
2012
Received:
March 14,
2012
Footnotes
The Conflict of Interest statement associated with this article can be found at http://dx.doi.org/10.1016/j.arth.2012.08.007.
Identification
Copyright
© 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
